Syvento sp. z o.o.

Research and experimental development on biotechnology

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2021-03-01
Share capital
1,800,000.00 PLN
Activity description

Syvento is a biotechnology company that offers development and formulation services for lipid-based nanocarriers and LNP technology. It specializes in creating lipid-based formulations for pharmaceutical products, including RNA-based drug products. The company provides solutions for encapsulating and delivering therapeutic molecules such as small molecules, RNA, DNA, and proteins.

Registered address
ul. Za Górą 19, 32-050 Skawina, Poland
Email
Phone
Social media
Electronic delivery address
AE:PL-32878-95697-EJDBS-19

Financials

Revenue history (in k)

From the notes

Current income tax (CIT due)$0

Filing timeliness

1 of 6 financial statements was filed late (for 2021, 91 days late). 1 of 6 audited by a statutory auditor.

  • 202510/07/2026
  • 202408/07/2025
  • 202312/07/2024
  • 202206/07/2023
  • 202114/10/2022
  • 202015/10/2021
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, city, voivodeship and across Poland in 2025.

Top 15%
City · Skawina146 / 285
Top 51%
Voivodeship · Małopolskie8,334 / 27,734
Top 30%
Country · Poland92,036 / 297,266
Top 31%

Results vs industry

Revenue
This companyUSD 970.44kMedianUSD 56.72kAverageUSD 2.72m
Net profit
This companyUSD -9.22mMedianUSD -1.27kAverageUSD -93.01k
Operating costs
This companyUSD 9.20mMedianUSD 66.48kAverageUSD 2.68m
Assets
This companyUSD 26.51mMedianUSD 134.71kAverageUSD 3.04m

News

SyVento BioTech at Cell & Gene Therapy International Europe 2026: From Innovation to GMP Manufacturing

SyVento BioTech at Cell & Gene Therapy International Europe 2026: From Innovation to GMP Manufacturing

SyVento BioTech will join Cell & Gene Therapy International Europe 2026, taking place on 3–5 November at Hotel Palace Berlin, Germany. The event brings together global biotechnology and pharmaceutical leaders to address one of the industry’s most pressing challenges: translating advanced therapeutic innovations into scalable, commercially viable manufacturing processes. As cell and gene therapies advance […]

SyVento BioTech at TIDES Europe 2026: Advancing RNA Therapeutics from Development to GMP Manufacturing

SyVento BioTech at TIDES Europe 2026: Advancing RNA Therapeutics from Development to GMP Manufacturing

SyVento BioTech will attend TIDES Europe 2026, taking place on 3–5 November at RAI Amsterdam, the Netherlands. Our representatives, Eliza Milewicz and Andreas Wendt, will meet with biotechnology and pharmaceutical companies seeking advanced RNA development, LNP delivery and GMP manufacturing solutions. TIDES Europe brings together global leaders in oligonucleotide, peptide and RNA therapeutics to address […]

Announcement of the merger plan of SyVento sp. z o.o. and ISONO Cosmetics sp. z o.o.

Announcement of the merger plan of SyVento sp. z o.o. and ISONO Cosmetics sp. z o.o.

Advancing Gene Therapy: SyVento BioTech at ESGCT 2026 in Hamburg

Advancing Gene Therapy: SyVento BioTech at ESGCT 2026 in Hamburg

The future of gene therapy depends on more than the ability to develop groundbreaking treatments. It depends on delivering them effectively, manufacturing them reliably and making them ready for clinical development. SyVento BioTech participated in the 33rd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT), held on 27–30 October 2026 at […]

From Rare Disease Innovation to Manufacturing Reality: SyVento BioTech at World Orphan Drug Congress Europe 2026

From Rare Disease Innovation to Manufacturing Reality: SyVento BioTech at World Orphan Drug Congress Europe 2026

Breakthrough science is transforming the future of rare disease treatment. But bringing innovative therapies to patients requires more than scientific discovery — it demands the right development and manufacturing strategy. SyVento BioTech participated in World Orphan Drug Congress Europe 2026, held on 27–28 October at RAI Amsterdam, joining the international rare disease community to explore […]

Beyond Vaccine Innovation: SyVento BioTech at World Vaccine Congress Europe 2026

Beyond Vaccine Innovation: SyVento BioTech at World Vaccine Congress Europe 2026

The next generation of vaccines will be defined not only by scientific breakthroughs, but by how effectively those breakthroughs can be translated into scalable, reliable manufacturing. SyVento BioTech joined World Vaccine Congress Europe 2026, held on 19–21 October at RAI Amsterdam, one of the industry’s leading gatherings connecting vaccine developers, biotechnology companies, pharmaceutical manufacturers and […]

Industry

Offer

  • Lipid formulations
  • mRNA synthesis
  • Drug delivery systems
  • Drug development
  • Fill and finish services

Websites

  • syvento.comSyVento BioTech: Extensive Expertise in mRNA Formulations & LNP Technology
    WordPress 7.1Google Tag ManagerYoast SEOWPMLLiteSpeed

Public procurement

The company is the contractor in one public sector contract, worth USD 18.10k.

SubjectAmount
Provision of encapsulation services
$18,098

Trademarks

The company holds 2 active trademarks registered with the Polish Patent Office. The first mark was filed in 2020.

MarkNumberClassesStatusProtected until
COVIDEZ (word)Z.5249815Protected Feb 22, 2031
COVIREX (word)Z.5114855Protected Mar 13, 2030
MarkProtected until
COVIDEZ (word)Feb 22, 2031
COVIREX (word)Mar 13, 2030

Job offers

The company lists 3 job openings on its own careers page: syvento.com/careers.

Position
Analytical specialist
Head of sterile filling department
Production specialist

Authorized Representatives

Radosław Kajetan Bartosik age 62 – President of the Management Board
Dominik Paweł Lipka age 43 – Management Board Member

Manner of representation

In the case of a one-person management board, declarations of will on behalf of the company are made and documents are signed by the member of the management board. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations of will and sign documents on behalf of the company.

Supervisory board

Eliza Aleksandra Milewicz age 47 – Supervisory Board Member
Piotr Robert Lipko age 35 – Supervisory Board Member
Tomasz Piec age 57 – Supervisory Board Member

Ownership

OwnerSharesShare valueStake
Ms Galleon Gmbh
30,000$486,223.66100%

Beneficial owners

Person

Capital group

The company belongs to the MS Galleon GmbH (Austria) group, which is its direct owner. The group has 15 companies, 5 of them abroad.

NameCountry
BarlinekPoland
Barlinek InwestycjePoland
CersanitPoland
EkovoltisPoland
FTF ColumbusPoland

Bank accounts

Registered as a VAT taxpayer on 2017-05-09.

Debt

No entries in the National Debtors Register (KRZ).

Real estate

TypeAmount
Buildings and premises
PLN 10.2M

MSiG notices

Publication dateEvent
Mar 17, 2021Transformation registered

Public aid

No public aid cases recorded in the last 10 years.

Regulatory authorisations

AuthorityTypeStatus
BDO register entry Active

Competitors

Name
JJP Biologics sp. z o.o.
Lipid Systems sp. z o.o.
Biotechna S.A.
Captor Therapeutics S.A.
Molecure S.A.
Aslab Science P.S.A.
Pikralida sp. z o.o.
Śląski Park Technologii Medycznych Kardio-Med Silesia sp. z o.o.
Nanogroup S.A.
Precisionlife Poland sp. z o.o.

Change history

DateEvent
2023-06-05Address change
2021-07-15Share capital increase
2021-03-01Entered in the register

FAQ

Last updated: 2026-10-07